Table 2.

Developmental and morphological defects from acute exposures to (a) DEHP and (b) MEHP in zebrafish embryos. * The concentration was converted from nM or µM using the molar mass of DEHP 390.57 g/mol. ** The concentration was converted from nM or µM using the molar mass of MEHP 278.34 g/mol.

(a) DEHP
Endpoint	Lowest Effective Dose	Exposure	Endpoint Time	References
hatching delayed	0.5 µg/L	27–72 hpf	72 hpf	[39]
	2.5 µg/L	4–48/72 hpf	48, 72 hpf	[44]
deformity rate increased	25 µg/L	3–168 hpf	168 hpf	[38]
	200 mg/L	1–168 hpf	168 hpf	[37]
body length decreased	* 2.0 µg/L	3–24 hpf	24 hpf	[45]
	100 mg/L	2–120 hpf	120 hpf	[46]
	100 mg/L	6–168 hpf	168 hpf	[47]
tail length decreased	* 2.0 µg/L	3–24 hpf	24 hpf	[45]
swim bladder inflation inhibited	500 µg/L	72–168 hpf	168 hpf	[41]
yolk sac edema	2.5 µg/L	4–72 hpf	72 hpf	[44]
	50 µg/L	2–48 hpf	48 hpf	[48]
yolk extension length decreased	* 2.0 µg/L	3–24 hpf	24 hpf	[45]
hyperemia	10 mg/L	72–168 hpf	168 hpf	[41]
dark pigmentation	10 mg/L	72–168 hpf	168 hpf	[41]
forebrain length decreased	* 2.0 µg/L	3–48 hpf	48 hpf	[45]
head width decreased	* 2.0 µg/L	3–24 hpf	24 hpf	[45]
(b) MEHP
Endpoint	Lowest Effective Dose	Exposure	Endpoint Time	References
hatching delayed	** 2.8 mg/L	4–76 hpf	76 hpf	[42]
deformity rate increased	** 14 mg/L	4–76 hpf	76 hpf	[42]
body length decreased	** 7.0 mg/L	4–76 hpf	76 hpf	[42]
body length decreased	** 8.4 mg/L	start at embryo stage—3/6 dpf	3/6 dpf	[50]
swim bladder abnormality	200 µg/L	6–96 hpf	96 hpf	[51]
no observed effect concentration (NOEC)	<6.09 mg/L	6–144 hpf	144 hpf	[49]
effective concentration, 10% (EC10)	9.77 mg/L	6–144 hpf	144 hpf	[49]
effective concentration, 50% (EC50)	29.98 mg/L	6–144 hpf	144 hpf	[49]
effective concentration, 100% (EC100)	50.0 mg/L	6–144 hpf	144 hpf	[49]